Beneficial effect of anti-platelet therapies on atherosclerotic lesion formation assessed by phase-contrast X-ray CT imaging

Int J Cardiovasc Imaging. 2012 Jun;28(5):1181-91. doi: 10.1007/s10554-011-9910-6. Epub 2011 Jun 19.

Abstract

We have applied an imaging system of phase-contrast X-ray CT to the detection of atherosclerotic plaque components by means of the differences of tissue mass densities. In this study, we investigated the effect of the anti-platelet therapies, widely used for secondly prevention of cardiovascular events, on plaque stability and examined whether this novel technique could detect the changes of plaque components under the therapy. Apolipoprotein E-deficient mice were fed on high-cholesterol diet alone and either with 0.1% cilostazol or clopidogrel for 10 weeks. We assessed atherosclerotic lesion volumes and components at brachiocephalic artery by the phase-contrast X-ray CT imaging and histochemistry. The phase-contrast X-ray CT imaging could reveal that cilostazol and clopidogrel significantly decreased atherosclerotic lesion volumes at brachiocephalic artery (31.2% reduction in cilostazol group and 37.4% reduction in clopidogrel group), compared with control group. In addition, the mass densities calculated by this method revealed the anti-platelet treatment increased stable plaque areas including high collagen content, but decreased unstable plaque areas including lipid and macrophage content. These findings were confirmed by histological analyses. Real-time PCR analyses indicated that anti-platelets inhibited gene expressions of cytokines and adhesion molecules, such as IFNγ and ICAM-1. Anti-platelet therapies had a beneficial effect on plaque stability maybe due to anti-inflammatory actions. Phase-contrast X-ray CT imaging could quantify the plaque volume and qualify the plaque components affected by anti-platelet therapies. This novel phase-contrast X-ray CT imaging system could be a plausible method to detect the unstable plaque non-invasively in the future.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta / drug effects
  • Aorta / metabolism
  • Aorta / pathology
  • Apolipoproteins E / deficiency
  • Apolipoproteins E / genetics
  • Atherosclerosis / diagnostic imaging*
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / genetics
  • Atherosclerosis / metabolism
  • Atherosclerosis / pathology
  • Body Weight
  • Brachiocephalic Trunk / diagnostic imaging*
  • Brachiocephalic Trunk / drug effects*
  • Brachiocephalic Trunk / pathology
  • Cell Adhesion Molecules / genetics
  • Cell Adhesion Molecules / metabolism
  • Cholesterol, Dietary
  • Cilostazol
  • Clopidogrel
  • Collagen / metabolism
  • Cytokines / genetics
  • Cytokines / metabolism
  • Disease Models, Animal
  • Gene Expression Regulation
  • Immunohistochemistry
  • Inflammation Mediators / metabolism
  • Lipids / blood
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Macrophages / pathology
  • Mice
  • Mice, Knockout
  • Plaque, Atherosclerotic
  • Platelet Aggregation Inhibitors / pharmacology*
  • RNA, Messenger / metabolism
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tetrazoles / pharmacology*
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / pharmacology
  • Tomography, X-Ray Computed*

Substances

  • Apolipoproteins E
  • Cell Adhesion Molecules
  • Cholesterol, Dietary
  • Cytokines
  • Inflammation Mediators
  • Lipids
  • Platelet Aggregation Inhibitors
  • RNA, Messenger
  • Tetrazoles
  • Collagen
  • Clopidogrel
  • Cilostazol
  • Ticlopidine